Aerie Pharmaceuticals is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.
The company's shares are not traded due to the acquisition by Alcon
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Aerie Pharmaceuticals news
22.11.2022
Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.
Source: 
investor.alcon.com
investor.alcon.com
23.08.2022
Alcon is buying Aerie Pharmaceuticals for $770 million, or 15.25 per share. Deal is scheduled to close in the fourth quarter of 2022.
Source: investor.alcon.com
investor.alcon.com
05.05.2022
The loss of Aerie Pharmaceuticals under GAAP for the 3 months of 2022 was $35.891 million, down 14.5% compared to $41.964 million in the previous year. Revenue increased 29.9% to $29.835 million from $22.97 million a year earlier.
Source: 
investors.aeriepharma.com
investors.aeriepharma.com
25.02.2022
Aerie Pharmaceuticals' GAAP net income for 2021 was $74.81 million, down 59.1% from $183.101 million in the previous year. Revenue increased 2.3 times to $194.134 million from $83.138 million a year earlier.
Source: investors.aeriepharma.com
investors.aeriepharma.com
General information
| Company name | Aerie Pharmaceuticals |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300 |
| Mailing address | 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 |
| Website | aeriepharma.com |
English (US) 